Skip to main content
. 2020 Jun 15;77(9):1–10. doi: 10.1001/jamaneurol.2020.1118

Table 3. Treatment-Emergent Adverse Effects.

Summary of treatment-emergent adverse events No./total No. (%)
Hookworm Placebo
Any serious treatment-emergent adverse event 2/35 (5.71) 4/36 (11.11)
Any nonserious treatment-emergent adverse event 35/35 (100.00) 33/36 (91.67)
Death 0 0
Discontinuation of treatment because of a treatment-emergent adverse event 0 0
Serious treatment-emergent adverse events Treated Placebo
Total participants affected by serious adverse events 2/35 (5.71) 4/36 (11.11)
Surgical and medical procedures
Hysterectomy 1/35 (2.86) 0/36 (0)
Thyroidectomy 0/35 (0) 1/36 (2.78)
Nervous system disorders
Multiple sclerosis relapse with hospital admission 0/35 (0) 1/36 (2.78)
Brain hypoxia due to cardiac arrest 0/35 (0) 1/36 (2.78)
Pregnancy 0/35 (0) 1/36 (2.78)
Skin disorders
Allergy to synthetic fabric 0/35 (0) 1/36 (2.78)
Back pain 0/35 (0) 2/36 (5.56)
Diabetes 1/35 (2.86) 0/36 (0)
Common treatment-emergent nonserious adverse events affecting ≥5% of patients
Gastrointestinal tract disorders
Diarrhea 9/35 (25.71) 9/36 (25.00)
Abdominal discomfort 8/35 (22.86) 6/36 (16.67)
Gastroenteritis 4/35 (11.43) 5/36 (13.89)
Constipation 1/35 (2.86) 3/36 (8.33)
Nausea 3/35 (8.57) 0/36 (0.00)
Urinary tract infection 7/35 (20.00) 6/36 (16.67)
Respiratory
Upper tract infections 16/35 (45.71) 18/36 (50.00)
Nasopharyngitis 3/35 (8.57) 2/36 (5.56)
Lower tract infections 3/35 (8.57) 3/36 (8.33)
Cough 2/35 (5.71) 2/36 (5.56)
Chest pain 2/35 (5.71) 0/36 (0.00)
Nervous system
Headache 1/35 (2.86) 6/36 (16.67)
Dizziness 0/35 (0) 2/36 (5.56)
Depression 2/35 (5.71) 1/36 (2.78)
Skin
Reaction at plaster site 29/35 (82.86) 10/36 (27.78)
Rash 3/35 (8.57) 3/36 (8.33)
Pain of skin 1/35 (2.86) 2/36 (5.56)
Musculoskeletal
Pain in extremity 2/35 (5.71) 7/36 (19.44)
Back pain 3/35 (8.57) 2/36 (5.56)
Other
Ear infection 0/35 (0) 3/36 (8.33)
Tooth abscess 3/35 (8.57) 3/36 (8.33)
Hay fever 1/35 (2.86) 3/36 (8.33)